What is the recommended salbutamol dose for acute bronchospasm (inhalation, nebulisation, oral, and intravenous) across different age groups?

Salbutamol Dosing for Acute Bronchospasm

For acute bronchospasm, use salbutamol 2-3 puffs (90 mcg/puff) via MDI every 4-6 hours for adults and children ≥4 years, or 2.5 mg via nebulization for children 2-12 years (weight-based: 0.1-0.15 mg/kg, max 2.5 mg) and adults (2.5 mg), administered 3-4 times daily. 1, 2

Inhalation (MDI/HFA)

Adults and children ≥4 years:

• Acute bronchospasm: 2 inhalations (180 mcg total) every 4-6 hours 2
• Each actuation delivers 90 mcg albuterol base from the mouthpiece
• Some patients may require only 1 inhalation every 4 hours
• More frequent administration or larger number of inhalations is NOT recommended 2

Exercise-induced bronchospasm prevention:

• 2 inhalations 15-30 minutes before exercise 2

Key technical points:

• Prime inhaler with 4 test sprays if first use or unused for >2 weeks 2
• Discard when dose counter reaches zero 2

Nebulization

Children 2-12 years (weight-based dosing):

• Initial dose: 0.1-0.15 mg/kg per dose 1
• Maximum: 2.5 mg per dose, 3-4 times daily 1
• Practical weight-based approach:
  • 10-15 kg (22-33 lbs): 1.25 mg (0.25 mL of 0.5% solution)

  • 15 kg (>33 lbs): 2.5 mg (0.5 mL of 0.5% solution) 1

• Dilute in 3 mL sterile normal saline 1

Adults and children >12 years:

• Standard dose: 2.5 mg (0.5 mL of 0.5% solution) 3-4 times daily 1
• Dilute with 2.5 mL sterile normal saline to total 3 mL 1
• Deliver over 5-15 minutes 1
• More frequent administration or higher doses NOT recommended 1

Important caveat: Research suggests fixed-dose 2.5 mg nebulization is as effective as weight-based dosing (0.1 mg/kg) in children with mild-moderate acute asthma 3, supporting the FDA-approved simplified dosing approach.

Route Comparison & Clinical Considerations

MDI with spacer vs nebulization:

• Recent high-quality evidence (2025) demonstrates MDI with holding chamber is equally effective as nebulization for mild-moderate exacerbations 4
• MDI approach results in:
  • Lower total salbutamol doses (0.10 vs 0.81 mg/kg) 4
  • Fewer hospitalizations, particularly in children <6 years (98.1% discharge vs 76.9%) 4
  • Shorter emergency department visits (1.7 vs 4.0 hours) 4
  • Fewer side effects, especially oxygen dependence 4

Safety profile:

• Nebulization associated with higher incidence of adverse reactions compared to MDI in children <2 years 5
• Neither formulation causes severe cardiac effects requiring treatment discontinuation 5, 6
• Standard doses do not significantly affect heart rate; only 5-10x standard dose (12.5-25 mg) causes clinically meaningful tachycardia 6

Oral Route (Not Recommended for Acute Bronchospasm)

While oral salbutamol exists, inhalation is superior for acute bronchospasm due to faster onset and fewer systemic side effects 7. Oral route may be considered only when inhalation is impossible.

Critical Pitfalls to Avoid

1. Do not exceed recommended dosing frequency - increasing use signals loss of asthma control requiring reassessment 8, 2
2. Do not use continuous nebulization without considering benzalkonium chloride - if bronchospasm doesn't resolve with high-dose nebulized salbutamol, paradoxical bronchospasm from preservative may be occurring 1
3. Do not withhold treatment due to tachycardia or cardiac history - evidence shows salbutamol is safe even in cardiac populations at standard doses 6
4. Back-to-back dosing may not be necessary - single dose provides similar bronchodilation as consecutive doses in children with initial SABA response 9